Article info
PDFCOVID-19
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
- Correspondence to Dr Tobias Janowitz, Cold Spring Harbor Laboratory; One Bungtown Road; Cold Spring Harbor, New York, USA; janowitz{at}cshl.edu; Kevin Tracey, The Feinstein Institute for Medical Research; Northwell Health; Manhasset, New York, New York; KJTracey{at}northwell.edu; Dr David Tuveson, Cold Spring Harbor Laboratory; One Bungtown Road; Cold Spring Harbor, New York, USA; dtuveson{at}cshl.edu
Citation
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Publication history
- Received May 19, 2020
- Revised May 20, 2020
- Accepted May 21, 2020
- First published June 4, 2020.
Online issue publication
April 15, 2021
Article Versions
- Previous version (15 April 2021).
- Previous version (15 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.